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Abstract: Clinically obvious reasons why children with neurological impairment (NMI) may be more severely affected  
in case of a viral respiratory tract infection include reduced vital capacity due to muscular weakness or spastic scoliosis, 
disturbed clearance of respiratory excretions (weak coughing and dysphagia), inability to comply actively with physio-
therapeutic interventions, recurrent micro-aspirations (gastroesophageal reflux disease, vomiting related to coughing), a 
history of frequent exposure to antibiotics and health care institutions, colonization with resistant pathogens, impaired 
immunologic defence mechanisms due to severe malnutrition and cachexia, and early clinical deterioration in case of high 
fever with metabolic acidosis and hypercapnia, and maybe associated seizures or febrile convulsions. 
Data from the literature suggests that in all children with NMI, who have to be hospitalized with severe clinical deteriora-
tion due to an airway infection, at least one specimen of nasopharyngeal secretions should be sent as soon as possible to  
a virologic laboratory to detect viral pathogens. Children with severe NMI and those mechanically ventilated for other  
reasons being hospitalized during the RSV season must be strictly protected against nosocomial RSV infection by means 
of standard and droplet precautions. Finally, children with severe NMI and age below 24 months of life should receive 
passive immunization with palivizumab following international recommendations.  
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INTRODUCTION 
  Respiratory syncytial virus (RSV) is one of the most fre-
quent causes of lower respiratory tract infection in infants 
and young children [1]. Most children have been infected   
at least once by 24 months of age [2], and 1 to 3% require 
hospitalization. The morbidity and mortality related to   
RSV infection is greater in prematurely born infants [3],   
particularly those with chronic lung disease [1, 4, 5] and   
infants with hemodynamically relevant congenital heart   
disease [6, 7]. 
  Based on these high risk groups, the American Associa-
tion of Paediatrics recommended criteria for prophylaxis 
with the humanized monoclonal antibody palivizumab [8]. 
For infants born between 32 and 35 weeks of gestation the 
policy statement referred to ‘epidemiologic data’ and rec-
ommended considering additional risk factors: “child care 
attendance, school-aged siblings, exposure to environmental 
air pollutants, congenital abnormalities of the airways, or 
severe neuromuscular disease” [8]. 
  Clinically obvious reasons why children with neurological 
impairment (NMI) may be more severely affected in case of 
a viral respiratory tract infection are given in Table 1 and 
have been extensively discussed by Panitch [9] and Resch 
[10]. Sritippayawan et al. [11] identified pneumonia as the 
most important reason for acute respiratory failure and for  
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the non-elective initiation of mechanical ventilation (69%) in 
73 children with NMI. Besides other confirmed environ-
mental and demographic risk factors for RSV lower respira-
tory tract disease [5] NMI was cited as a risk factor in par-
ticular as comorbidity in preterm infants born between 32 
and 35 weeks of gestation [12]. 
DATA ON RSV-INFECTION IN CHILDREN WITH 
PRE-EXISTING NEUROMUSCULAR IMPAIRMENT 
  In a subgroup analysis of the Canadian PICNIC RSV-
database, Arnold and co-workers [13] compared the outcome 
of RSV infection in children with CLD with those having 
other chronic conditions such as NMI, cystic fibrosis and 
pulmonary malformation. In that study the proportions of 
patients admitted to the intensive care unit and of those me-
chanically ventilated were not significantly different between 
premature infants with CLD and children with NMI, sup-
porting the hypothesis that children with NMI face an in-
creased risk of complications. These results referred only to 
6 retrospectively identified patients (NMI subgroup). Five of 
these 6 children with NMI were older than 12 months. 
  Resch and co-workers [14] from Graz/Austria identified 
45 prematurely born infants with clinically significant   
neurologic handicaps in their retrospective single centre   
cohort study, which included 453 infants with a gestational 
age at birth of 29-36 weeks of gestation. The NMI rate was 
26% in infants born at 29-32 weeks of gestation and 5% in 
those born at 33-36 weeks. In a multivariate analysis, NMI 
was confirmed as a significant independent risk factor for 
rehospitalization (21% vs. 9%; OR 2.93; CI95 1.44-5.97; 156    The Open Microbiology Journal, 2011, Volume 5  Simon et al. 
p<0.001). The same group reported in 2006 the results of an 
Austrian multicenter observational study, in which 801 pre-
mature infants with a gestational age at birth of 29-32 weeks 
were included [15]. These children represented 60-70% of all 
infants born in Austria in this age group during the surveil-
lance period (2001-2003). Of all these preterms, 84 (10.5%) 
had neurologic disease and 30 (3.8%) were classified as suf-
fering from ‘severe neurological disease’. Although presence 
of NMI doubled the risk of rehospitalization in the univariate 
analysis, the confidence interval (CI95) of the odds ratio in 
multivariate analysis failed to prove a significant difference 
(OR 2.16; CI95 0.77-5.25) [15]. 
  The first prospective multicenter study confirming the 
hypothesis that hospitalized children with clinically relevant 
NMI run an increased risk for severe RSV-disease, was a 
study published from our group, in which six consecutive 
RSV seasons were covered [16]. The surveillance took place 
in 14 paediatric hospitals in Germany from 1999-2005. In 
total, 1568 RSV infections were prospectively documented 
in 1541 paediatric inpatients. Of these, 73 (4.7%) patients 
displayed a clinically relevant NMI; 41 (56%) NMI patients 
had at least one additional risk factor for a severe course of 
the infection (multiple risk factors in some patients; prema-
turity in 30, congenital heart disease in 19, chronic lung dis-
ease 6, and immunodeficiency in 8). Median age at diagnosis 
was higher in NMI patients (14 mo vs. 5 mo), NMI patients 
had a greater risk of seizures (15.1% vs. 1.6%), and a higher 
proportion in the NMI group had to be mechanically venti-
lated (9.6% vs. 1.9%). Eventually, the attributable mortality 
was significantly higher in the NMI group (5.5% vs. 0.2%; 
p<0.001 for all). Multivariate logistic regression confirmed 
that NMI was independently associated with PICU admis-
sion (odds ratio 4.94; 95% confidence interval 2.69 to 8.94; 
p<0.001] and mechanical ventilation (OR 3.85; 1.28 to 
10.22; p=0.017). Our study did not document higher rates  
of pneumonia in children with NMI. This suggests that   
radiologically confirmed pneumonia is not a prerequisite for 
respiratory failure in these patients. Even infections of the 
upper respiratory tract lead to an increase in nasopharyngeal 
and tracheal secretions, which cannot be cleared by the   
patients because of muscle weakness and an impaired cough 
mechanism [17]. Any acute viral infection, in particular if 
associated with airway obstruction [18] could aggravate res-
piratory muscle fatigue and predispose children with NMI to 
severe hypoxemia and hypercapnia. As shown previously by 
others [19], even children, who are on prolonged mechanical 
ventilation for other reasons are at risk for nosocomial RSV 
infection.  
  Thorburn and co-workers [19-21] from the Department 
of Paediatric Intensive Care, Royal Liverpool Children's 
Hospital-Alder Hey, have investigated the role of RSV infec-
tion in paediatric intensive care unit (PICU) in a sequence of 
three interesting studies. In the most recently published co-
hort study comprising all children with severe RSV infection 
from eight consecutive RSV seasons (1999-2007), the 
authors included 406 RSV-positive patients admitted to 
PICU. Of these, 98.5% required mechanical ventilation and 
35 children (8,6%) died [median age 5.1 months; interquar-
tile range (IQR) 2.4-13.6)]. The median length of PICU stay 
in the subgroup with fatal outcome was 16 days (IQR 8-31). 
The median age in 371 survivors was 2.5 months (IQR 1.2-
9) with a corresponding median length of PICU stay of 5 
days (IQR 4-9). During the study period 2009 RSV-positive 
patients were admitted to the children's hospital, giving an 
overall hospital RSV mortality rate of 1.7%.  
  Of the deaths, 18 were directly RSV related (RSV bron-
chiolitis-related mortality PICU 4.4% and hospital 0.9%) as 
the patients were still RSV positive when they died and 17 
children died from non-pneumonitis causes after becoming 
RSV negative.  
  All of the RSV deaths had pre-existing medical condi-
tions--chromosomal abnormalities 29%, cardiac lesions 
27%, neuromuscular impairment 15%, chronic lung disease 
12%, large airway abnormality 9%, and immunodeficiency 
9%. Nineteen children (56%) had pre-existing disease in two 
or more organ systems [relative risk (RR) 4.38]. Predispos-
ing risk factors for death were pre-existing disease (RR 
2.36), cardiac anomaly (RR 2.98) and nosocomial/hospital-
acquired RSV infection (RR 2.89). An interaction effect was 
Table 1.  Pathogenesis of Complications in Patients with Neurologic Impairment and Viral Respiratory Tract Infection [Adopted 
from Panitch HB 2004 [9]] 
•  Reduced vital capacity due to muscular weakness or spastic scoliosis
# 
•  Disturbed clearance of respiratory excretions (weak coughing and dysphagia) 
•  Inability to comply actively with physiotherapeutic interventions. 
•  Recurrent micro-aspiration (gastroesophageal reflux disease, vomiting related to coughing) 
•  History of frequent exposure to antibiotics and health care institutions (admissions); Colonization with resistant pathogens (i.e. Pseudomonas spp., 
Acinetobacter spp.) 
•  Impaired immunologic defence mechanisms due to severe malnutrition and cachexia 
•  Early clinical deterioration in case of high fever with metabolic acidosis and hypercapnia 
•  Seizures, febrile convulsions 
•  Rhabdomyolysis /acute myositis triggered by viral infection* 
# May result in a cor pulmonale in adolescents 
* One patient in the NMI group of our study [16] experienced rhabdomyolysis temporally related to the RSV infection. This complication has been reported by others [28]. Respiratory Syncytial Virus Infection in Children with Neuromuscular Impairment  The Open Microbiology Journal, 2011, Volume 5    157 
observed between pre-existing disease, nosocomial RSV 
infection and mortality (p<0.001). Data on the prior receipt 
of palivizumab prophylaxis have not been reported consider-
ing this population as it was only introduced into clinical 
practice late in the study period and therefore any impact 
would be difficult to ascertain. 
  Von Renesse an co-workers [22] recently focused on the 
subgroup of patients ventilated for other reasons at the time 
of the RSV infection. Referring to the risk factors which 
have been confirmed for severe RSV disease, 60% (n=12) of 
the patients in the group ventilated mechanically showed at 
least one additional risk factor for a severe course of the viral 
respiratory tract infection:  
-  50% (n=10) were born prematurely,  
-  20% (n=4) had a chronic lung disease with dependence 
on oxgen supplementation in the last 6 months, 
-  In 35% (n=7), congenital heart disease had been docu-
mented.  
  The frequency of pneumonia was 40% in the group venti-
lated mechanically and 20% in the control group. Signifi-
cantly more patients in the group ventilated mechanically 
received antibiotic treatment (85% vs. 45%, P = 0.008),   
and attributable mortality was higher in the group ventilated 
mechanically (15% [n = 3] vs. 0% in the control group,   
P = 0.231). The median length of hospitalization was 31 days 
in the group ventilated mechanically (range 4–257 days), and 
12 days in the control group (range 4–206 days, P=0.05). 
  Despite existing consensus recommendations, only two 
of these high risk patients (10%) had received the recom-
mended palivizumab prophylaxis. Children treated by long 
term mechanical ventilation may acquire RSV infection by 
transmission by droplets and via contact to caregivers and 
healthcare workers. Fourty percent of all RSV infections in 
these children were nosocomial RSV infections.  
  In a landmark study published in JAMA in 2005, Keren 
and coworkers [23] confirmed a strong association between 
the presence of NMI and the development of respiratory 
failure in children with influenza virus infection. This was 
confirmed by a recent 2003-2004 surveillance study of   
severe paediatric influenza cases (hospitalization in the   
PICU or death) in California: 23% (36 of 160) children had a 
neurologic disorder as an underlying condition [24].  
CONCLUSIONS 
  Taken together, these data from the literature suggests 
that  
-  In all children with neuromuscular impairment, who have 
to be hospitalized with severe clinical deterioration   
due to an airway infection, at least one specimen of   
nasopharyngeal secretions should be sent as soon as   
possible to a virologic laboratory to detect viral patho-
gens [25, 26].  
-  Children with severe neuromuscular impairment and 
those mechanically ventilated for other reasons being 
hospitalized during the RSV season must be strictly pro-
tected against nosocomial RSV infection by means of 
standard and droplet precautions [19, 20, 27]. 
-  Children with severe neuromuscular disease, in particular 
those within the first 24 months of life, should receive 
passive immunization with palivizumab following the   
actual recommendations [8]. 
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